Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia

Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia

Abstract The FDA-approved DNA hypomethylating agents (DHAs) like 5-azacytidine (5AC) and decitabine (DAC) demonstrate efficacy in the treatment of hematologic malignancies. Despite previous reports that showed histone acetylation changes upon using these agents, the exact mechanism underpinning thes...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hetty E. Carraway, Sridhar A. Malkaram, Yana Cen, Aymen Shatnawi, Jun Fan, Hamdy E. A. Ali, Zakaria Y. Abd Elmageed, Thomm Buttolph, James Denvir, Donald A. Primerano, Tamer E. Fandy
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/d954e9fb12024afa8636559b800189b6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares